Forte Biosciences Tops Q2 Loss Forecasts

Forte Biosciences (NASDAQ:FBRX), a clinical-stage biotech developing treatments for autoimmune diseases, released its results for Q2 2025 on August 14, 2025. The company reported a GAAP net loss per share of $(0.96) for Q2 2025, which was better than the analyst estimate of $(1.11) (GAAP) for Q2 2025 and a significant improvement from the prior-year’s GAAP net loss of $(6.78) per share in Q2 2024. There was no revenue, in line with expectations for an early-stage biotech. Operating losses moderated year over year on a GAAP basis in Q2 2025, with notable reductions in administrative spending despite higher research and development costs as the company advanced its main pipeline asset. The quarter reflected a solid infusion of new capital and progress across Forte’s clinical programs. Source: Analyst estimates for the quarter provided by FactSet. Forte Biosciences specializes in developing immunology medicines, focusing on FB102, a biologic therapy targeting autoimmune conditions. Its central research area includes diseases such as celiac disease, vitiligo (a skin disorder causing loss of skin color), and alopecia areata (an autoimmune-related hair loss condition). The company’s business model revolves around pushing its lead drug candidate through clinical trials to unlock value, aiming for regulatory approval and future commercial use.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool